Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.

Dasgupta T, Haas-Kogan DA.

Front Oncol. 2013 May 10;3:110. doi: 10.3389/fonc.2013.00110. eCollection 2013.

2.

BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.

Olow A, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss W, Resnick AC, Waanders AJ, Stalpers LJ, Berger MS, Gupta N, James CD, Petritsch CK, Haas-Kogan DA.

Clin Cancer Res. 2016 Nov 1;22(21):5312-5321. Epub 2016 May 23.

PMID:
27217440
3.
4.

Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas.

Tian Y, Rich BE, Vena N, Craig JM, Macconaill LE, Rajaram V, Goldman S, Taha H, Mahmoud M, Ozek M, Sav A, Longtine JA, Lindeman NI, Garraway LA, Ligon AH, Stiles CD, Santagata S, Chan JA, Kieran MW, Ligon KL.

J Mol Diagn. 2011 Nov;13(6):669-77. doi: 10.1016/j.jmoldx.2011.07.002. Epub 2011 Aug 30.

5.

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.

Barrett D, Brown VI, Grupp SA, Teachey DT.

Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000. Review.

6.

Low Grade Gliomas in Children.

Chalil A, Ramaswamy V.

J Child Neurol. 2016 Mar;31(4):517-22. doi: 10.1177/0883073815599259. Epub 2015 Aug 18. Review.

PMID:
26286938
7.

Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.

Gierke M, Sperveslage J, Schwab D, Beschorner R, Ebinger M, Schuhmann MU, Schittenhelm J.

J Cancer Res Clin Oncol. 2016 Jan;142(1):89-100. doi: 10.1007/s00432-015-2006-2. Epub 2015 Jun 27.

PMID:
26115961
8.

Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas.

Penman CL, Faulkner C, Lowis SP, Kurian KM.

Front Oncol. 2015 Mar 3;5:54. doi: 10.3389/fonc.2015.00054. eCollection 2015. Review.

9.

A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.

Ho CY, Mobley BC, Gordish-Dressman H, VandenBussche CJ, Mason GE, Bornhorst M, Esbenshade AJ, Tehrani M, Orr BA, LaFrance DR, Devaney JM, Meltzer BW, Hofherr SE, Burger PC, Packer RJ, Rodriguez FJ.

Acta Neuropathol. 2015 Oct;130(4):575-85. doi: 10.1007/s00401-015-1467-3. Epub 2015 Aug 12.

PMID:
26264609
10.

Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.

Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):5957-62. doi: 10.1073/pnas.1219232110. Epub 2013 Mar 26. Erratum in: Proc Natl Acad Sci U S A. 2013 May 21;110(21):8750.

11.

Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.

Robinson JP, Vanbrocklin MW, Lastwika KJ, McKinney AJ, Brandner S, Holmen SL.

Oncogene. 2011 Mar 17;30(11):1341-50. doi: 10.1038/onc.2010.513. Epub 2010 Nov 8.

12.

Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma.

Studebaker A, Bondra K, Seum S, Shen C, Phelps DA, Chronowski C, Leasure J, Smith PD, Kurmasheva RT, Mo X, Fouladi M, Houghton PJ.

Pediatr Blood Cancer. 2015 Oct;62(10):1768-74. doi: 10.1002/pbc.25579. Epub 2015 May 15.

14.

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.

Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE, Piccart-Gebhart MJ.

Cancer Treat Rev. 2013 Dec;39(8):935-46. doi: 10.1016/j.ctrv.2013.03.009. Epub 2013 May 3.

PMID:
23643661
15.

BRAF, GNAQ, and GNA11 mutations and copy number in pediatric low-grade glioma.

Laviv Y, Toledano H, Michowiz S, Dratviman-Storobinsky O, Turm Y, Fichman-Horn S, Kagnovski E, Goldenberg-Cohen N.

FEBS Open Bio. 2012 Jun 1;2:129-34. doi: 10.1016/j.fob.2012.05.004. Print 2012.

16.

Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.

Lefranc F, Rynkowski M, DeWitte O, Kiss R.

Adv Tech Stand Neurosurg. 2009;34:3-35. Review.

PMID:
19368079
17.

Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.

Zhang J, Yao TW, Hashizume R, Hariono S, Barkovich KJ, Fan QW, Prados M, James CD, Weiss WA, Nicolaides T.

J Neurooncol. 2017 Feb;131(3):495-505. doi: 10.1007/s11060-016-2333-4. Epub 2016 Nov 15.

PMID:
27848137
18.

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.

Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A.

Acta Neuropathol. 2011 Mar;121(3):397-405. doi: 10.1007/s00401-011-0802-6. Epub 2011 Jan 29.

PMID:
21274720
19.

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.

Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.

Int J Cancer. 2013 Nov;133(9):2089-101. doi: 10.1002/ijc.28236. Epub 2013 May 29.

20.

New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model.

Raabe E, Kieran MW, Cohen KJ.

Clin Cancer Res. 2013 Sep 1;19(17):4553-8. doi: 10.1158/1078-0432.CCR-13-0662. Epub 2013 Jul 23.

Supplemental Content

Support Center